IRON vs. AUPH, NRIX, ALXO, SVRA, PRAX, PRTC, PHAR, ELVN, TYRA, and YMAB
Should you be buying Disc Medicine stock or one of its competitors? The main competitors of Disc Medicine include Aurinia Pharmaceuticals (AUPH), Nurix Therapeutics (NRIX), ALX Oncology (ALXO), Savara (SVRA), Praxis Precision Medicines (PRAX), PureTech Health (PRTC), Pharming Group (PHAR), Enliven Therapeutics (ELVN), Tyra Biosciences (TYRA), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical preparations" industry.
Disc Medicine (NASDAQ:IRON) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, community ranking, profitability and media sentiment.
Disc Medicine has a beta of 0.18, meaning that its share price is 82% less volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500.
Disc Medicine has a net margin of 0.00% compared to Aurinia Pharmaceuticals' net margin of -44.45%. Aurinia Pharmaceuticals' return on equity of -20.10% beat Disc Medicine's return on equity.
83.7% of Disc Medicine shares are held by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 4.7% of Disc Medicine shares are held by insiders. Comparatively, 4.3% of Aurinia Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Disc Medicine had 3 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 6 mentions for Disc Medicine and 3 mentions for Aurinia Pharmaceuticals. Disc Medicine's average media sentiment score of 0.60 beat Aurinia Pharmaceuticals' score of 0.19 indicating that Disc Medicine is being referred to more favorably in the media.
Disc Medicine has higher earnings, but lower revenue than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.
Disc Medicine currently has a consensus price target of $57.29, indicating a potential upside of 89.19%. Aurinia Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 103.67%. Given Aurinia Pharmaceuticals' higher probable upside, analysts clearly believe Aurinia Pharmaceuticals is more favorable than Disc Medicine.
Aurinia Pharmaceuticals received 543 more outperform votes than Disc Medicine when rated by MarketBeat users. Likewise, 73.03% of users gave Aurinia Pharmaceuticals an outperform vote while only 71.88% of users gave Disc Medicine an outperform vote.
Summary
Disc Medicine beats Aurinia Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Disc Medicine News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Disc Medicine Competitors List
Related Companies and Tools
